Given that p53 is frequently mutated in a wide range of human cancers, with approximately 70% of these mutations being missense types (Sabapathy and Lane 2018), and that radiation therapy is used in over 50% of cancer patients without accounting for the molecular variations among similar tumor types (Allen et al. 2017), it is crucial to elucidate the specific molecular effects of individual p53 point mutations, particularly concerning radioresistance. This evidence concerns the gene TP53 and cancer.